Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Income from Continuing Operations (2020 - 2025)

Maxcyte (MXCT) has disclosed Income from Continuing Operations for 6 consecutive years, with 9596000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 9.45% to 9596000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 44630000.0 through Dec 2025, down 8.71% year-over-year, with the annual reading at 44630000.0 for FY2025, 8.71% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 9596000.0 at Maxcyte, up from 12416000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 9306900.0 in Q4 2021, with the low at 12416000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 7603985.0, with a median of 9450500.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations surged 57.12% in 2021, then plummeted 167.55% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 9306900.0 in 2021, then plummeted by 151.68% to 4809600.0 in 2022, then fell by 9.74% to 5278000.0 in 2023, then tumbled by 100.78% to 10597000.0 in 2024, then grew by 9.45% to 9596000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 9596000.0, 12416000.0, and 12357000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.